New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
08:33 EDTMRKMerck announces Canadian approval for GRASTEK tablets
Merck announced the regulatory approval and launch of GRASTEK sublingual tablets in Canada. This represents the first approval of GRASTEK for Merck. The product is currently marketed by ALK-Abello in Europe as GRAZAX. Merck previously announced that the U.S. Food and Drug Administration had accepted for review Biologics License Applications for GRASTEK and for its investigational ragweed sublingual allergy immunotherapy tablet. Merck expects the FDAs review for both to be completed in 1H14. Merck has partnered with ALK-Abello to develop its sublingual allergy immunotherapy tablets for Timothy grass pollen, ragweed pollen and house dust mite-induced allergic rhinitis in North America.
News For MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information
August 20, 2015
11:33 EDTMRKLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
08:38 EDTMRKMerck says to present new analyses from IMPROVE-IT study
Subscribe for More Information
August 18, 2015
12:13 EDTMRKMerck recalls Temodar, Temozolomide bottles with cracked caps
Subscribe for More Information
08:03 EDTMRKMerck says FDA accepts sBLA for Keytruda
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use